ClinVar Miner

Submissions for variant NM_004612.4(TGFBR1):c.-13T>C

gnomAD frequency: 0.00020  dbSNP: rs886063220
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Laboratory Services, Illumina RCV000403385 SCV000475603 uncertain significance Loeys-Dietz syndrome 2016-06-14 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000298980 SCV000475604 uncertain significance Loeys-Dietz syndrome 1 2016-06-14 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000356175 SCV000475605 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2016-06-14 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000589811 SCV000698482 uncertain significance not provided 2017-06-14 criteria provided, single submitter clinical testing Variant summary: The TGFBR1 c.-13T>C variant involves the alteration of a non-conserved nucleotide in the 5UTR region. One in silico tool predicts a benign outcome for this variant. 4/5 splice prediction tools predict no significant impact on normal splicing. ESE finder predicts that this variant may affect ESE sites. However, these predictions have yet to be confirmed by functional studies. This variant was found in 5/26312 control chromosomes, predominantly observed in the European (Non-Finnish) subpopulation at a frequency of 0.000372 (5/13448). This frequency is about 198 times the estimated maximal expected allele frequency of a pathogenic TGFBR1 variant (0.0000019), suggesting this is likely a benign polymorphism found primarily in the populations of European (Non-Finnish) origin. However, this genomic site was noted to be in a low-quality site in gnomAD, thus this data needs to be taken with caution. The fact that this variant is residing within the sequence of GGC GGT/C GGC GGC makes it more prone to false postive calls. In addition, one other clinical diagnostic laboratory classified this variant as uncertain significance, without evidence for independent evaluation. The variant of interest has not, to our knowledge, been reported in affected individuals via publications; nor evaluated for functional impact by in vivo/vitro studies. Taken together, this variant is classified as VUS-possibly benign until more evidence becomes available.
Fulgent Genetics, Fulgent Genetics RCV002481248 SCV002782406 uncertain significance Loeys-Dietz syndrome 1; Multiple self-healing squamous epithelioma 2021-10-19 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.